![]() patients who are PD-L1 negative by various assays still respond to combination therapies. Lee then spoke about the roles of genetic mutations in prognosis and treatment decision-making.Īggen: Although PD-L1 has been studied as a companion biomarker, it often doesn’t change our treatment decision for our patients with kidney cancer. Next, Aggen spoke about current approaches to biomarker testing. The future is bright for our patients with RCC. Now we are going to the 10-year anniversary. After approval of immunotherapy-based combinations, it’s not unusual that we have patients with advanced metastatic RCC a great response to therapy and are still alive after 5 years. Overall, we a big improvement in treatment options for patients with RCC in the last decade. Due to recent approvals of adjuvant immunotherapy in kidney cancers and also clinical trials in the perioperative setting, I also see a number of patients with localized stage III after nephrectomy, and they come to us for a discussion of adjuvant therapy. To start the conversation, Bilen spoke about the prognosis of RCC and recent advances in care.īilen: In a regular week, I see close to 30 patients with kidney cancers, and a majority of them have metastatic clear cell RCC. Prognosis, Biomarkers, and Care Advancements Here, we summarize the conversation with these thought leaders, who explored all facets of care, from incidence through treatment and beyond. “These combination therapies have really been game-changers for patients.” ![]() “We’re very fortunate that in the past 3 to 4 years, we have a wealth of treatment options for patients who have metastatic kidney cancer,” said Aggen. Alter, MD, co-chief of Urologic Oncology and Head & Neck Oncology at the John Theurer Cancer Center in Hackensack, New Jersey Arnab Basu, MD, MPH, assistant professor at the University of Alabama at Birmingham School of Medicine Mehmet Asim Bilen, MD, director of the Genitourinary Medical Oncology Program at Winship Cancer Institute of Emory University in Atlanta, Georgia and Chung-Han Lee, MD, MPH, of Memorial Sloan Kettering Cancer Center, shared their thoughts on recent advances in treatment options for metastatic RCC and commented on emerging data in the field. Aggen, MD, PhD, of the Memorial Sloan Kettering Cancer Center in New York Robert S. In an OncView® conversation with CancerNetwork®, David H. Systemic treatment of renal cell carcinoma (RCC) is an evolving field, with newer combination regimens supplanting older single-agent tyrosine kinase inhibitors (TKIs) as the standard of care (SOC). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |